The Citeline Awards, sponsored by Informa Pharma Intelligence, today announced that Neumentum Inc. and NEMA Research, Inc., have been nominated and are in consideration for an award this year for Most Successful Early-Phase Research Company. Neumentum is pioneering the development of a powerful, effective nonopioid analgesic agent for use to control postoperative pain. This early-phase research study was designed to test the safety and toxicology of a 48-hour continuous infusion regimen of ketorolac tromethamine (NTM-001) which is intended to provide stable plasma levels of ketorolac rather than the peaks and troughs of bolus dosing. This 48-hour continuous infusion regimen is groundbreaking, and the study successfully demonstrated its safety and toxicology.
Neumentum Inc., a pharmaceutical company dedicated to transforming the way pain is treated – without opioids – today announced that Scott Shively, Chief Executive Officer and co-founder of Neumentum, and Dr. Joseph Pergolizzi, Executive Chairman and co-founder of Neumentum, will provide a brief corporate update at the UBS Virtual Biotechnology Private Company Symposium on Wednesday, September 22, 2021 at 4:00PM ET. Management will also host investor meetings during the conference.
MORRISTOWN, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Neumentum Inc., a pharmaceutical company dedicated to transforming the way pain is treated – without opioids – today announced data on NTM-006, the company’s Phase 2 investigational non-opioid, non-NSAID analgesic candidate that may have the potential to replace opioids, at the PAINWeek Conference 2021, taking place September 7-11, 2021 in Las Vegas, Nevada.
MORRISTOWN, N.J., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Neumentum Inc., a pharmaceutical company dedicated to transforming the way pain is treated – without opioids – will present three posters at the American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting and Exhibition, being held virtually December 6-10, 2020.
MORRISTOWN, N.J., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Neumentum Inc., a pharmaceutical company dedicated to transforming the way pain is treated – without opioids – today announced that the company has entered into a license agreement with Nuance Biotech Co. Ltd (Nuance), a China based specialty pharmaceutical company, providing Nuance with the exclusive rights to develop and commercialize Neumentum’s novel ketorolac for IV infusion (NTM-001) in China. NTM-001, is a novel, alcohol-free formulation of ketorolac in a convenient to use pre-mixed bag for continuous 24 hours IV infusion, for the treatment of moderately severe acute pain requiring analgesia at the opioid level, usually in a postoperative setting.
 Neumentum Inc., a pharmaceutical company dedicated to transforming the way pain is treated – without opioids – will present two posters with data on NTM-006, a new chemical entity (NCE) non-opioid, non-NSAID analgesic candidate that may have the potential to replace opioids, at PAINWeek 2020 Live Virtual Conference, being held on September 11-13, 2020.
Neumentum has licensed a midphase oral analgesic from Johnson & Johnson. The agreement covers an asset that came through a phase 2 pain trial in 2015 only to stall following the completion of the study.